CALGARY, Nov. 18, 2016 /CNW/ - Crown Capital Partners Inc. ("Crown") (TSX: CRN), which provides growth capital to successful mid-market companies, today announced the closing of a $60.0 million term loan (the "Agreement") with Medicure Inc. ("Medicure") (TSXV: MPH), a specialty pharmaceutical company focused on the development and commercialization of cardiac therapeutics for the U.S. hospital market. Headquartered in Winnipeg, Medicure's lead product is Aggrastat ®, which is marketed in the U.S. for non-ST elevation acute coronary syndrome. Medicure reports that sales of Aggrastat have been growing rapidly over the past several years, and the product now accounts for approximately 40% of the patient share of the market for this class of drugs in the U.S., compared with only 3% share in 2012. Medicure's revenue and EBITDA has grown significantly as the company's market share has increased. Medicure also owns a minority interest in Apicore US, a fast-growing Active Pharmaceutical Ingredient manufacturing service provider and developer of generic products for pharmaceutical companies. Medicure will use the proceeds of the term loan to purchase an additional 60% of the outstanding shares of Apicore. "Medicure is a well-managed, profitable and growing company that has demonstrated consistent revenue and EBITDA growth over the past several years," said Chris Johnson, Crown's President & CEO. "Building off this strong base business, they are acquiring a controlling interest in a highly attractive business, and we're pleased to support them in executing this major transaction." The Agreement provides for a $60.0 million term loan to Medicure, of which Crown Capital Fund IV, LP ("Crown IV LP"), an investment fund managed by Crown in which Crown holds a 40% interest, will advance $30 million. On closing of the Agreement, Crown syndicated $30.0 million of the loan to Ontario Pension Board ("OPB"), a limited partner in Crown's funds. Mr. Johnson added: "We are delighted with OPB's participation in this transaction. They have been a supportive limited partner for many years and their co-investment in Medicure demonstrates the strength of our limited partner relationships."